Cited by 1,625COVID-19 Clinical Research StudiesRespiratory Support and MechanismsSARS-CoV-2 and COVID-19 Research

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

Open access

Geleris, Joshua, Sun, Yifei, Platt, Jonathan, Zucker, Jason, Baldwin, Matthew, Hripcsak, George, Labella, Angelena, Manson, Daniel K., Kubin, Christine, Barr, R. Graham, Sobieszczyk, Magdalena E., Schluger, Neil W.·2020·New England Journal of Medicine

DOI 10.1056/nejmoa2012410PMC PMC7224609

Open this paper in CoChat — free account

Abstract

BACKGROUND: Hydroxychloroquine has been widely administered to patients with Covid-19 without robust evidence supporting its use. METHODS: We examined the association between hydroxychloroquine use and intubation or death at a large medical center in New York City. Data were obtained regarding consecutive patients hospitalized with Covid-19, excluding those who were intubated, died, or discharged within 24 hours after presentation to the emergency department (study baseline). The primary end point was a composite of intubation or death in a time-to-event analysis. We compared outcomes in patients who received hydroxychloroquine with those in patients who did not, using a multivariable Cox model with inverse probability weighting according to the propensity score. RESULTS: Of 1446 consecutive patients, 70 patients were intubated, died, or discharged within 24 hours after presentation and were excluded from the analysis. Of the remaining 1376 patients, during a median follow-up of 22.5 days, 811 (58.9%) received hydroxychloroquine (600 mg twice on day 1, then 400 mg daily for a median of 5 days); 45.8% of the patients were treated within 24 hours after presentation to the emergency department, and 85.9% within 48 hours. Hydroxychloroquine-treated patients were more severely ill at baseline than those who did not receive hydroxychloroquine (median ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen, 223 vs. 360). Overall, 346 patients (25.1%) had a primary end-point event (180 patients were intubated, of whom 66 subsequently died, and 166 died without intubation). In the main analysis, there was no significant association between hydroxychloroquine use and intubation or death (hazard ratio, 1.04, 95% confidence interval, 0.82 to 1.32). Results were similar in multiple sensitivity analyses. CONCLUSIONS: In this observational study involving patients with Covid-19 who had been admitted to the hospital, hydroxychloroquine administration was not associated with either a greatly lowered or an increased risk of the composite end point of intubation or death. Randomized, controlled trials of hydroxychloroquine in patients with Covid-19 are needed. (Funded by the National Institutes of Health.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2012410

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Gautret, P., Lagier, J., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Esteves-Vieira, V., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288
Retracted
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L. Y., Dong, E., Song, C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa237 · Cited by 2,696
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
Devaux, C. A., Rolain, J., Colson, P., & Raoult, D. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105938 · Cited by 1,122
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial
Borba, M. G. S., Val, F. F. A., Sampaio, V. S., Alexandre, M. A. A., Melo, G. C., Brito, M., Mourão, M. P. G., Brito-Sousa, J. D., Baía-da-Silva, D., Guerra, M. V. F., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.8857 · Cited by 1,038
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trialPreprint
Chen, Z., Hu, J., Zhang, Z., Jiang, S., Han, S., Yan, D., Zhuang, R., Hu, B., & Zhang, Z. (2020) · medRxiv · doi:10.1101/2020.03.22.20040758 · Cited by 861
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].
Chen, J., Liu, D., Liu, L., Liu, P., Xu, Q., Xia, L., Ling, Y., Huang, D. F., Song, S., Zhang, D., et al. (2020) · PubMed Central · doi:10.3785/j.issn.1008-9292.2020.03.03 · Cited by 662
Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection
Fantini, J., Scala, C. D., Chahinian, H., & Yahi, N. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105960 · Cited by 566
Mechanism of action of hydroxychloroquine as an antirheumatic drug
Fox, R. I. (1993) · Seminars in Arthritis and Rheumatism · doi:10.1016/s0049-0172(10)80012-5 · Cited by 430
Design and Synthesis of Hydroxyferroquine Derivatives with Antimalarial and Antiviral Activities
Biot, C., Daher, W., Leleu‐Chavain, N., Fandeur, T., Khalife, J., Dive, D., & Clercq, E. D. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0601856 · Cited by 318

Flagged first, then by citations

Show all 17 references

Sorted by citations

Items 401–500 of 1,000

Drugs that offer the potential to reduce hospitalization and mortality from SARS-CoV-2 infection: The possible role of the sigma-1 receptor and autophagy
Brimson, J. M., Prasanth, M. I., Malar, D. S., Brimson, S., Thitilertdecha, P., & Tencomnao, T. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1952987 · Cited by 36
Synthesis, crystal structure and in silico studies of novel 2,4-dimethoxy-tetrahydropyrimido[4,5- b ]quinolin-6(7 H )-ones
Patel, S. G., Vala, R. M., Patel, P. J., Upadhyay, D. B., Ramkumar, V., Gardas, R. L., & Patel, H. M. (2022) · RSC Advances · doi:10.1039/d2ra02694e · Cited by 36
COVID-19: imbalanced cell-mediated immune response drives to immunopathology
Wang, J., Li, Q., Qiu, Y., & Lu, H. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2122579 · Cited by 36
COVID-19 treatment: Much research and testing, but far, few magic bullets against SARS-CoV-2 coronavirus
Kouznetsov, V. V. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112647 · Cited by 35
Empiric Therapeutic Anticoagulation and Mortality in Critically Ill Patients With Respiratory Failure From SARS‐CoV‐2: A Retrospective Cohort Study
Ferguson, J. G., Volk, S., Vondracek, T. G., Flanigan, J., & Chernaik, A. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1749 · Cited by 35
Recommendations for the Diagnosis, Prevention, and Control of Coronavirus Disease-19 in Children—The Chinese Perspectives
Feng, F., Chen, Y., Zhao, D., Tonglin, L., Huang, Y., Qiu, L., Hao, Y., Hu, X., Yin, W., Liu, Z., et al. (2020) · Frontiers in Pediatrics · doi:10.3389/fped.2020.553394 · Cited by 35
Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity
Lin, K. J., Schneeweiß, S., Tesfaye, H., D’Andrea, E., Liu, J., Lii, J., Murphy, S. N., & Gagne, J. J. (2020) · Drugs · doi:10.1007/s40265-020-01424-7 · Cited by 35
Recommendations for treatment of critically ill patients with COVID-19
Kluge, S., Janssens, U., Welte, T., Weber‐Carstens, S., Schälte, G., Salzberger, B., Gastmeier, P., Länger, F. P., Welper, M., Westhoff, M., et al. (2020) · Der Anaesthesist · doi:10.1007/s00101-020-00879-3 · Cited by 35
Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?
Machiels, J. D., Bleeker‐Rovers, C. P., ter Heine, R., Rahamat-Langendoen, J. C., de Mast, Q., ten Oever, J., Bousema, T., van Crevel, R., & Wertheim, H. F. L. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106056 · Cited by 35
Tratamiento farmacológico de la COVID-19: revisión narrativa de los Grupos de Trabajo de Enfermedades Infecciosas y Sepsis (GTEIS) y del Grupo de Trabajo de Transfusiones Hemoderivados (GTTH)
Dı́az, E., Menéndez, R. A., Vidal, P., Escapa, M. G., Suberviola, B., Serrano, A., Marcos-Neira, P., Quintana‐Díaz, M., & González, M. C. (2020) · Medicina Intensiva · doi:10.1016/j.medin.2020.06.017 · Cited by 34
Review on therapeutic targets for COVID-19: insights from cytokine storm
Júnior, M. L. D. M. S., de Souza, L. M. A., Dutra, R. E. M. C., Valente, R. G. D. M., & Melo, T. S. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2020-138791 · Cited by 34
The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients
Ayerbe, L., Risco-Risco, C., & Ayis, S. A. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02505-x · Cited by 34
Immunomodulation for Severe COVID-19 Pneumonia: The State of the Art
Zhang, Y., Chen, Y., & Meng, Z. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.577442 · Cited by 34
Hydroxychloroquine plus standard of care compared with standard of care alone in COVID-19: a meta-analysis of randomized controlled trials
Amani, B., Khanijahani, A., & Amani, B. (2021) · Scientific Reports · doi:10.1038/s41598-021-91089-3 · Cited by 34
Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group
Palanques-Pastor, T., Megías‐Vericat, J. E., Martı́nez, P., Lorenzo, J. L. L., Navascués, J. C., Macias, G. R., Cano, I., Sangerman, M. A., Vicente, M. B. V., Algarra, J. L., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1948031 · Cited by 34
Adsorption of chloroquine and hydroxychloroquine as potential drugs for SARS-CoV-2 infection on BC 3 nanosheets: a DFT study
Rahimi, R., Solimannejad, M., & Farghadani, M. (2021) · New Journal of Chemistry · doi:10.1039/d1nj03084a · Cited by 34
Deep Learning for Drug Discovery: A Study of Identifying High Efficacy Drug Compounds Using a Cascade Transfer Learning Approach
Zhuang, D., & Ibrahim, A. K. (2021) · Applied Sciences · doi:10.3390/app11177772 · Cited by 33
Coronavirus disease 2019 in an orthotopic liver transplant recipient living with human immunodeficiency virus
Modi, A., Koval, C. E., Taege, A. J., Esfeh, J. M., Eghtesad, B., Menon, K. V., Quintini, C., & Miller, C. C. (2020) · Transplant Infectious Disease · doi:10.1111/tid.13351 · Cited by 33
Pharmacokinetics-Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: a Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents
Zeitlinger, M. A., Koch, B. C. P., Brüggemann, R. J. M., Cock, P. A. J. G. D., Felton, T., Hites, M., Lê, J., Luque, S., MacGowan, A. P., Marriott, D. J. E., et al. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00924-9 · Cited by 33
Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists
Niaki, O. Z., Anadkat, M. J., Chen, S. T., Fox, L. P., Harp, J., Micheletti, R. G., Nambudiri, V. E., Pasieka, H. B., Shinohara, M. M., Rosenbach, M. A., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.06.051 · Cited by 33
Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine – from HIV-1 infection to COVID-19
Naghipour, S., Ghodousi, M., Rahsepar, S., & Elyasi, S. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1792291 · Cited by 33
Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients
Li, L., Wang, X., Wang, R., Hu, Y., Jiang, S., & Lu, X. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s259058 · Cited by 33
Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments
Goodarzi, P., Mahdavi, F., Mirzaei, R., Hasanvand, H., Sholeh, M., Zamani, F., Sohrabi, M., Tabibzadeh, A., Jeda, A. S., Niya, M. H. K., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106885 · Cited by 33
Inhibition of SARS-CoV-2 Entry into Host Cells Using Small Molecules
Adem, K. A., Shanti, A., Stefanini, C., & Lee, S. (2020) · Pharmaceuticals · doi:10.3390/ph13120447 · Cited by 33
Hospital Length of Stay for Patients with Severe COVID-19: Implications for Remdesivir’s Value
Anderson, M. R., Bach, P. B., & Baldwin, M. R. (2020) · PharmacoEconomics - Open · doi:10.1007/s41669-020-00243-6 · Cited by 33
Self-citation
Chloroquine may induce endothelial injury through lysosomal dysfunction and oxidative stress
Gregório, P., da Cunha, R. S., Biagini, G., Bosquetti, B., Budag, J., Ortíz, A., Sánchez-Niño, M. D., Barreto, F. C., & Stinghen, A. E. M. (2021) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2021.115412 · Cited by 33
Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulations
Mahdian, S., Zarrabi, M., Panahi, Y., & Dabbagh, S. (2021) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2021.100541 · Cited by 33
Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study
Joo, E., Ko, J., Kim, S. E., Kang, S., Baek, J. H., Heo, E. Y., Shi, H. J., Eom, J. S., Choe, P. G., Bae, S., et al. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e83 · Cited by 33
COVID-19 in Solid Organ Transplant Recipients in Spain Throughout 2020: Catching the Wave?
Coll, E., Fernández‐Ruiz, M., Padilla, M., Moreso, F., Hernández, A. M. G., Yañez, Í., Molina, M., Vázquez-Sánchez, T., Crespo, M., Facundo, C., et al. (2021) · Transplantation · doi:10.1097/tp.0000000000003873 · Cited by 33
Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study from Denmark
Cordtz, R., Kristensen, S., Dalgaard, L. P. H., Westermann, R., Duch, K. S., Lindhardsen, J., Torp-Pedersen, C. T., & Dreyer, L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173842 · Cited by 33
An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19)
Bahrami, A. A., Azargoonjahromi, A., Sadraei, S., Aarabi, A., Payandeh, Z., & Rajabibazl, M. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00339-3 · Cited by 33
HRS/EHRA/APHRS/LAHRS/ACC/AHA Worldwide Practice Update for Telehealth and Arrhythmia Monitoring During and After a Pandemic
Varma, N., Marrouche, N. F., Aguinaga, L., Albert, C. M., Arbelo, E., Choi, J., Chung, M. K., Conte, G., Dagher, L., Epstein, L. M., et al. (2020) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.120.009007 · Cited by 32
COVID-19 associated complications and potential therapeutic targets
Monpara, J. D., Sodha, S., & Gupta, P. K. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173548 · Cited by 32
An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19
Fu, W., Liu, Y., Liu, L., Hu, H., Cheng, X., Liu, P., Song, Z., Zha, L.-J., Bai, S., Xu, T., et al. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100547 · Cited by 33
Coronavirus in human diseases: Mechanisms and advances in clinical treatment
Lin, P., Wang, M., Wei, Y., Kim, T., & Wei, X. (2020) · MedComm · doi:10.1002/mco2.26 · Cited by 32
Chloroquine and hydroxychloroquine for combating COVID-19: Investigating efficacy and hypothesizing new formulations using Bio/chemoinformatics tools
Hathout, R. M., AbdelHamid, S. G., & Metwally, A. A. (2020) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2020.100446 · Cited by 32
Repurposing therapeutic agents against SARS-CoV-2 infection: most promising and neoteric progress
Hossain, M. J., & Rahman, S. M. A. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1864327 · Cited by 32
Inpatient use of metformin and acarbose is associated with reduced mortality of COVID‐19 patients with type 2 diabetes mellitus
Li, J., Wei, Q., McCowen, K. C., Xiong, W., Liu, J., Jiang, W., Thomas, R. L., Hepokoski, M., He, M., Shyy, J. Y. J., et al. (2021) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.301 · Cited by 32
AYUSH-64 as an adjunct to standard care in mild to moderate COVID-19: An open-label randomized controlled trial in Chandigarh, India
Singh, H., Srivastava, S., Yadav, B., Rai, A. K., Jameela, S., Muralidharan, S., Mohan, R., Chaudhary, S., Singhal, R., Rana, R. K., et al. (2022) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2022.102814 · Cited by 32
Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity
Hache, G., Rolain, J., Gautret, P., Deharo, J., Brouqui, P., Raoult, D., & Honoré, S. (2021) · Microbial Drug Resistance · doi:10.1089/mdr.2020.0232 · Cited by 32
COVID‐SAFER : Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults
Ross, S. B., Wilson, M. G., Papillon‐Ferland, L., Elsayed, S., Wu, P. E., Battu, K., Porter, S., Rashidi, B., Tamblyn, R. M., Pilote, L., et al. (2020) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16623 · Cited by 31
Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19
Delaleu, J., Deniau, B., Battistella, M., de Masson, A., Bensaïd, B., Jachiet, M., Lazaridou, I., Bagot, M., Bouaziz, J., Archer, G., et al. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.05.046 · Cited by 31
Drug treatment of coronavirus disease 2019 (COVID-19) in China.
Jin, Z., Liu, J.-Y., Feng, R., Ji, L., Jin, Z.-L., & Li, H. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173326 · Cited by 31
HRS/EHRA/APHRS/LAHRS/ACC/AHA worldwide practice update for telehealth and arrhythmia monitoring during and after a pandemic
Varma, N., Marrouche, N. F., Aguinaga, L., Albert, C. M., Arbelo, E., Choi, J., Chung, M. K., Conte, G., Dagher, L., Epstein, L. M., et al. (2020) · Journal of Arrhythmia · doi:10.1002/joa3.12389 · Cited by 31
Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused
Chaudhary, S., Natt, B., Bime, C., Knox, K. S., & Glassberg, M. K. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00539 · Cited by 31
Case Report: COVID-19 Associated Renal Infarction and Ascending Aortic Thrombosis
Mukherjee, A., Ghosh, R., & Furment, M. M. (2020) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.20-0869 · Cited by 31
COVID-19 Among Patients With Inflammatory Rheumatic Diseases
Esatoğlu, S. N., Taşçılar, K., Babaoğlu, H., Beş, C., Yurttaş, B., Akar, S., Pehlivan, Ö., Akleylek, C., Tecer, D., Seyahi, E., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.651715 · Cited by 31
The time to offer treatments for COVID-19
Ngo, B., Marik, P. E., Kory, P. D., Shapiro, L., Thomadsen, R., Iglesias, J. I., Ditmore, S., Rendell, M., Varón, J., Dubé, M. P., et al. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1901883 · Cited by 31
Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in FrancePreprint
Sbidian, É., Josse, J., Lemaitre, G., Meyer, I., Bernaux, M., Gramfort, A., Lapidus, N., Paris, N., Neuraz, A., Lerner, I., et al. (2020) · medRxiv · doi:10.1101/2020.06.16.20132597 · Cited by 31
Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings
Gasperetti, A., Biffi, M., Duru, F., Schiavone, M., Ziacchi, M., Mitacchione, G., Lavalle, C., Saguner, A. M., Lanfranchi, A. K., Casalini, G., et al. (2020) · EP Europace · doi:10.1093/europace/euaa216 · Cited by 30
A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients
Giossi, R., Menichelli, D., Pani, A., Tratta, E., Romandini, A., Roncato, R., Nani, A., Schenardi, P. A., Diani, E., Fittipaldo, V. A., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.698008 · Cited by 30
Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU
Başaran, N. Ç., Uyaroğlu, O. A., Dizman, G. T., Özışık, L., Şahin, T. K., Taş, Z., İnkaya, A. Ç., Karahan, S., Alp, Ş., Alp, A., et al. (2020) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2006-173 · Cited by 30
The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse
Morrisette, T., Lodise, T. P., Scheetz, M. H., Goswami, S., Pogue, J. M., & Rybak, M. J. (2020) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00325-2 · Cited by 30
Remdesivir Use in Patients Requiring Mechanical Ventilation due to COVID-19
Lapadula, G., Bernasconi, D. P., Bellani, G., Soria, A., Rona, R., Bombino, M., Avalli, L., Rondelli, E., Cortinovis, B., Colombo, E., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa481 · Cited by 30
Current Approaches to COVID-19: Therapy and Prevention
Dixit, S., Khatib, K. I., Bandopadhyay, S., Shrivastav, O., & Mhatre, U. (2020) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-23470 · Cited by 30
Chloroquine, hydroxychloroquine, and COVID-19: Systematic review and narrative synthesis of efficacy and safety
Takla, M., & Jeevaratnam, K. (2020) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2020.11.003 · Cited by 30
Drug repurposing for the treatment of COVID-19: Pharmacological aspects and synthetic approaches
Batalha, P. N., Forezi, L. D. S. M., Lima, C. G. S., Pauli, F. P., Boechat, F. D. C. S., de Souza, M. C. B. V., Cunha, A. C., Ferreira, V. F., & da Silva, F. D. C. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104488 · Cited by 30
Optimal control of the SIR model in the presence of transmission and treatment uncertainty
Gatto, N. M., & Schellhorn, H. (2021) · Mathematical Biosciences · doi:10.1016/j.mbs.2021.108539 · Cited by 30
Mining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics
Zhu, H., Chen, C. Z., Sakamuru, S., Zhao, J., Ngan, D. K., Simeonov, A. M., Hall, M. D., Xia, M., Zheng, W., & Huang, R. (2021) · Scientific Reports · doi:10.1038/s41598-021-86110-8 · Cited by 30
Repurposing medications
Novack, G. D. (2020) · The Ocular Surface · doi:10.1016/j.jtos.2020.11.012 · Cited by 30
Antiviral and antibacterial activity of hand sanitizer and surface disinfectant formulations
Filipe, H. A. L., Fiuza, S. M., Henriques, C. A., & Antunes, F. E. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121139 · Cited by 30
Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease
AlQahtani, M., Kumar, N., Aljawder, D., Abdulrahman, A., Mohamed, M. W., Alnashaba, F., Fayyad, M. A., Alshaikh, F. S., Alsahaf, F., Saeed, S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-08794-w · Cited by 30
Who's in the Crowd Matters: Cognitive Factors and Beliefs Predict Misinformation Assessment Accuracy
Kaufman, R. A., Haupt, M. R., & Dow, S. P. (2022) · Proceedings of the ACM on Human-Computer Interaction · doi:10.1145/3555611 · Cited by 30
Arbidol treatment with reduced mortality of adult patients with COVID-19 in Wuhan, China: a retrospective cohort studyPreprint
Liu, Q., Fang, X., Tian, L., Vankadari, N., Chen, X., Wang, K., Li, D., Dai, X., Xu, F., Shen, L., et al. (2020) · medRxiv · doi:10.1101/2020.04.11.20056523 · Cited by 30
Potential Therapeutic Agents and Associated Bioassay Data for COVID-19 and Related Human Coronavirus Infections
Zhou, Q. A., Kato-Weinstein, J., Li, Y., Deng, Y., Granet, R., Garner, L. V., Liu, C., Polshakov, D. A., Gessner, C., & Watkins, S. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00074 · Cited by 29
Empfehlungen zur intensivmedizinischen Therapie von Patienten mit COVID-19 – 3. Version
Kluge, S., Janssens, U., Welte, T., Weber‐Carstens, S., Schälte, G., Salzberger, B., Gastmeier, P., Länger, F. P., Wepler, M., Westhoff, M., et al. (2020) · Der Anaesthesist · doi:10.1007/s00101-020-00833-3 · Cited by 29
Management of SARS‐CoV‐2 pneumonia
Sagnelli, C., Celia, B., Monari, C., Cirillo, S., Angelis, G. D., Bianco, A., & Coppola, N. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26470 · Cited by 29
The Rise and Fall of Hydroxychloroquine for the Treatment and Prevention of COVID-19
Lee, Z., Rayner, C. R., Forrest, J. I., Nachega, J. B., Senchaudhuri, E., & Mills, E. J. (2020) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.20-1320 · Cited by 29
Design and in silico study of the novel coumarin derivatives against SARS-CoV-2 main enzymes
Özdemir, M., Köksoy, B., Ceyhan, D., Sayın, K., Erçağ, E., Bulut, M., & Yalçın, B. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1863263 · Cited by 29
Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials
Bignardi, P. R., Vengrus, C. S., Aquino, B. D. M., & Neto, A. C. (2021) · Pathogens and Global Health · doi:10.1080/20477724.2021.1884807 · Cited by 29
Repurposing Chloroquine Against Multiple Diseases With Special Attention to SARS-CoV-2 and Associated Toxicity
Kamat, S., & Kumari, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.576093 · Cited by 29
Willingness to participate in COVID-19 vaccine trials; a survey among a population of healthcare workers in Uganda
Kitonsa, J., Kamacooko, O., Bahemuka, U. M., Kibengo, F., Kakande, A., Wajja, A., Basajja, V., Lumala, A., Ssemwanga, E., Asaba, R., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251992 · Cited by 29
Adverse Cardiovascular Effects of Anti-COVID-19 Drugs
Liu, D., Zeng, X., Ding, Z., Lv, F., Mehta, J. L., & Wang, X. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.699949 · Cited by 29
Efficacy of Chloroquine and Hydroxychloroquine for the Treatment of Hospitalized COVID-19 Patients: A Meta-Analysis
Deng, J., Zhou, F., Heybati, K., Ali, S. H., Zuo, Q., Hou, W., Dhivagaran, T., Ramaraju, H. B., Chang, O., Wong, C. Y., et al. (2021) · Future Virology · doi:10.2217/fvl-2021-0119 · Cited by 29
Mechanism of Action of Small-Molecule Agents in Ongoing Clinical Trials for SARS-CoV-2: A Review
Zhao, L., Li, S., & Zhong, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.840639 · Cited by 29
Recent advances in small-molecular therapeutics for COVID-19
Zhong, L., Zhao, Z., Peng, X., Zou, J., & Yang, S. (2022) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbac024 · Cited by 29
“Cytokine storm”, not only in COVID-19 patients. Mini-review
Lukán, N. (2020) · Immunology Letters · doi:10.1016/j.imlet.2020.09.007 · Cited by 29
Azithromycin in Hospitalised Patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialPreprint
Horby, P., Roddick, A., Spata, E., Staplin, N., Emberson, J., Pessoa-Amorim, G., Peto, L., Campbell, M., Brightling, C., Prudon, B., et al. (2020) · medRxiv · doi:10.1101/2020.12.10.20245944 · Cited by 29
A consulta de enfermagem no enfrentamento da COVID-19: vivências na atenção primária à saúde
Fermo, V. C., Alves, T. F., Böell, J. E. W., & Tourinho, F. S. V. (2021) · Revista Eletrônica de Enfermagem · doi:10.5216/ree.v23.65893 · Cited by 28
Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review
Patel, T. K., Barvaliya, M. J., Kevadiya, B. D., Patel, P. B., & Bhalla, H. L. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-020-09930-x · Cited by 28
The impact of the SARS‐CoV‐2 infection, with special reference to the hematological setting
Sica, A., Casale, D., Rossi, G., Casale, B., Ciccozzi, M., Fasano, M., Ciotti, M., Sagnelli, E., Papa, A., & Sagnelli, C. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26197 · Cited by 28
Low-dose radiotherapy for COVID-19 pneumonia treatment: case report, procedure, and literature review
Del-Castillo-Pacora, R., Martinez, D., Bardales, G. J. S., Pinillos, L., Garcia, B., Castillo, L., Carhuactocto, A., Giordano, F. A., & Sarria, G. R. (2020) · Strahlentherapie und Onkologie · doi:10.1007/s00066-020-01675-z · Cited by 28
COVID‐19 und Immunregulation – von grundlegenden und translationalen Aspekten zu klinischen Implikationen
Schön, M. P., Berking, C., Biedermann, T., Buhl, T., Erpenbeck, L., Eyerich, K., Eyerich, S., Ghoreschi, K., Goebeler, M., Ludwig, R. J., et al. (2020) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14169_g · Cited by 28
Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead
Singh, H., Chauhan, P., & Kakkar, A. K. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173717 · Cited by 28
RETRACTED ARTICLE: Detection of SARS-CoV-2 from patient fecal samples by whole genome sequencing
Papoutsis, A. J., Borody, T. J., Dolai, S., Daniels, J., Steinberg, S., Barrows, B., & Hazan, S. (2021) · Gut Pathogens · doi:10.1186/s13099-021-00398-5 · Cited by 29
Retracted
Renal Involvement in COVID-19: A Review of the Literature
Migliaccio, M. G., Mauro, M. D., Ricciolino, R., Spiniello, G., Carfora, V., Verde, N., Mottola, F. F., & Coppola, N. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s288869 · Cited by 28
Clinical outcome of patients with COVID-19 Pneumonia treated with corticosteroids and colchicine in Colombia
Pinzón, M. A., Arango, D. C., Betancur, J. F., Ortiz, S., Holguín, H., Arias, C. A., Palacio, B. J. M., Amarillo, M., Llano, J. F., & Montoya, P. (2021) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-021-00460-9 · Cited by 28
Current trends and geographical differences in therapeutic profile and outcomes of COVID-19 among pregnant women - a systematic review and meta-analysis
Dubey, P., Thakur, B., Reddy, S., Martinez, C. A., Nurunnabi, M., Manuel, S. L., Chheda, S., Bracamontes, C., & Dwivedi, A. K. (2021) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-021-03685-w · Cited by 28
Clinical Management of COVID-19: A Review of Pharmacological Treatment Options
Heustess, A., Allard, M., Thompson, D. K., & Fasinu, P. S. (2021) · Pharmaceuticals · doi:10.3390/ph14060520 · Cited by 28
Machine Learning for Predicting the 3-Year Risk of Incident Diabetes in Chinese Adults
Wu, Y., Hu, H., Cai, J., Chen, R., Zuo, X., Cheng, H., & Yan, D. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.626331 · Cited by 28
Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics
Kumar, S., Çalışkan, D. M., Janowski, J., Faist, A., Conrad, B. C. G., Lange, J., Ludwig, S., & Brunotte, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.752227 · Cited by 28
Oral Methioninase for Covid-19 Methionine-restriction Therapy
Hoffman, R. M., & Han, Q. (2020) · In Vivo · doi:10.21873/invivo.11948 · Cited by 28
Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: Risks and benefits at the time of COVID ‐19 pandemic
Infante, M., Ricordi, C., & Fabbri, A. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13053 · Cited by 27
QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin
Hsia, B. C., Greige, N., Quiroz, J. A., Khokhar, A., Daily, J. P., Biase, L. D., Ferrick, K. J., Fisher, J. D., & KRUMERMAN, A. K. (2020) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-020-00822-x · Cited by 27
Systematic review and meta‐analysis of effectiveness of treatment options against SARS‐CoV‐2 infection
Chandrasekar, V. T., Venkatesulu, B. P., Patel, H. K., Spadaccini, M., Manteuffel, J. J., & Ramesh, M. S. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26302 · Cited by 27
Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease
Satlin, M. J., Goyal, P., Magleby, R., Maldarelli, G. A., Pham, K., Kondo, M., Schenck, E. J., Rennert, H., Westblade, L. F., Choi, J. J., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236778 · Cited by 27
Hydroxychloroquine use in COVID-19: is the risk of cardiovascular toxicity justified?
Stevenson, A., Kirresh, A. Z., Conway, S., White, L., Ahmad, M., & Little, C. D. (2020) · Open Heart · doi:10.1136/openhrt-2020-001362 · Cited by 27
The Potential Role of Coagulation Factor Xa in the Pathophysiology of COVID-19: A Role for Anticoagulants as Multimodal Therapeutic Agents
Frydman, G. H., Streiff, M. B., Connors, J. M., & Piazza, G. (2020) · TH Open · doi:10.1055/s-0040-1718415 · Cited by 27
Potential COVID‐19 Therapeutic Agents and Vaccines: An Evidence‐Based Review
Khani, E., Khiali, S., & Entezari‐Maleki, T. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1822 · Cited by 27
A Narrative Review of Pharmacologic Treatments for COVID ‐19: Safety Considerations and Ototoxicity
Little, C. C., & Cosetti, M. K. (2021) · The Laryngoscope · doi:10.1002/lary.29424 · Cited by 27

Authors: Geleris, J., Sun, Y., Platt, J., Zucker, J., Baldwin, M., Hripcsak, G., Labella, A., Manson, D. K., Kubin, C., Barr, R. G., Sobieszczyk, M. E., & Schluger, N. W.
Affiliations: Columbia University Irving Medical Center (US)
Corresponding author: Schluger, Neil W.
ORCID: Geleris, Joshua
Sun, Yifei
Platt, Jonathan
Zucker, Jason
Baldwin, Matthew
Hripcsak, George
Manson, Daniel K.
Kubin, Christine
Barr, R. Graham
Sobieszczyk, Magdalena E.
Schluger, Neil W.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2020-06-18
Volume: 382
Issue: 25
Pages: 2411-2418
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2012410
PMC: PMC7224609
OpenAlex: W3023346879
Cited by: 1,625
References: 17
Citations by year: 2026: 16 · 2025: 23 · 2024: 57 · 2023: 80 · 2022: 167 · 2021: 440 · 2020: 839
FWCI: 49.99
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (RO1-HL077612, RO1-HL093081, RO1-HL121270, RO1-LM006910)
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (200-2009-32593)
Topics: Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory Support and Mechanisms
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Keywords: hydroxychloroquine, COVID-19 pandemic, mechanical ventilation, intubation, mortality, hospitalized patients, antimalarial drugs, treatment efficacy, propensity score weighting, SARS-CoV-2
MeSH terms: Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Adult, Aged, Aged, 80 and over, Female, Hospitalization, Humans, Hydroxychloroquine, Intubation, Male, Middle Aged, New York City, Pneumonia, Viral, Treatment Failure, Coronavirus Infections, Propensity Score, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks